Mitsubishi UFJ Asset Management
TGTX icon

Mitsubishi UFJ Asset Management’s TG Therapeutics TGTX Stock Holding History

Mitsubishi UFJ Asset Management’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$259K Sell
4,717
-1,319
-22% -$54K ﹤0.01% 990
2026
Q1 		$201K Sell
6,036
-135
-2% -$4.02K ﹤0.01% 980
2025
Q4 		$181K Buy
6,171
+741
+14% +$24.2K ﹤0.01% 1033
2025
Q3 		$196K Buy
5,430
+9
+0.2% +$296 ﹤0.01% 996
2025
Q2 		$195K Buy
+5,421
New +$202K ﹤0.01% 978

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Mitsubishi UFJ Asset Management's TGTX Position: Q2 2026 in Review

Mitsubishi UFJ Asset Management reduced its TG Therapeutics (TGTX) stake by 22% in Q2 2026, selling an estimated $54K and leaving 4,717 shares worth $259K. The position accounts for ﹤0.01% of the portfolio, ranked #990.

Mitsubishi UFJ Asset Management first reported a position in TGTX in Q2 2025 and has held it in 5 quarters since. 427 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

  • Mitsubishi UFJ Asset Management held 4,717 shares of TG Therapeutics worth $259K as of Q2 2026.
  • Mitsubishi UFJ Asset Management sold 1,319 TG Therapeutics shares in Q2 2026, an estimated $54K.
  • TG Therapeutics made up ﹤0.01% of Mitsubishi UFJ Asset Management's portfolio in Q2 2026, its #990 holding.
  • Mitsubishi UFJ Asset Management first reported a position in TG Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • 427 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Mitsubishi UFJ Asset Management's 13F filing for Q2 2026, filed 7 Aug 2026.